SecBot SecBot
SECBOTREPLAY Home › Report › DNLI

DNLI · Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus…

Denali Therapeutics Inc. · PRESS-RELEASE filed May 7, 2026 at 16:01 ET

At the news

BULLISHIMPACT 7/10

PRESS-RELEASE filed May 7, 2026 at 16:01 ET

Denali reported Q1 2026 EPS of -$0.69, a slight beat vs consensus -$0.71, but the headline is the FDA approval and U.S. launch of AVLAYAH (tividenofusp alfa) for Hunter syndrome, the first medicine to cross the blood-brain barrier via transferrin receptor. The company also secured $200M in royalty financing and has a robust pipeline with key readouts expected by end of 2026.

  • FDA accelerated approval of AVLAYAH (tividenofusp alfa) for Hunter syndrome on March 25, 2026
  • First commercial patients dosed in April 2026; launch operational with payers engaged
  • Received $200M gross proceeds from Royalty Pharma synthetic royalty funding agreement
  • Cash, cash equivalents and marketable securities of $1.05B as of March 31, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access